Cyclic AMP-Mediated Inhibition of Cholesterol Catabolism in <i>Mycobacterium tuberculosis</i> by the Novel Drug Candidate GSK2556286
Kirstin Brown, Kaley M. Wilburn, Christine R. Montague, J.C. Grigg, Olalla Sanz, Esther Pérez‐Herrán, David Barros, Lluís Ballell, Brian C. VanderVen, Lindsay D. Eltis
Abstract
Despite the deployment of combination tuberculosis (TB) chemotherapy, efforts to identify shorter, nonrelapsing treatments have resulted in limited success. Recent evidence indicates that GSK2556286 (GSK286), which acts via Rv1625c, a membrane-bound adenylyl cyclase in Mycobacterium tuberculosis , shortens treatment in rodents relative to standard of care drugs.
Topics & Concepts
Mycobacterium tuberculosisCatabolismDrugMicrobiologyTuberculosisPharmacologyCholesterolChemistryBiologyVirologyMedicineBiochemistryEnzymePathologyTuberculosis Research and EpidemiologySteroid Chemistry and BiochemistryBiochemical and Molecular Research